BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//TrialSonar//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:TrialSonar · $INCY readouts
X-WR-CALDESC:Clinical-trial primary completion dates from ClinicalTrials.go
 v\, refreshed nightly by TrialSonar. Not investment advice.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT04509700-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261105
DTEND;VALUE=DATE:20261106
SUMMARY:Parsaclisib readout (P2) · Incyte Corporation $INCY
DESCRIPTION:Rollover Study to Provide Continued Treatment for Participants 
 With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (IN
 CB050465)\n\nPrimary completion date: 2026-11-05 (estimated)\nOriginally p
 lanned: 2025-05-26 (+17.3 months)\nPhase 2 · Oncology · B-Cell Malignanc
 ies\nEnrollment: 112 · Sites: 105\n\nPrimary completion = last participan
 t's primary-endpoint data collected\; topline results usually follow weeks
  to months later. Sponsor-reported\, often an estimate. Not investment adv
 ice.\n\nhttps://datacutoff.com/radar.html?nct=NCT04509700\nhttps:/
 /clinicaltrials.gov/study/NCT04509700
URL:https://datacutoff.com/radar.html?nct=NCT04509700
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05851443-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261120
DTEND;VALUE=DATE:20261121
SUMMARY:povorcitinib readout (P2) · Incyte Corporation $INCY
DESCRIPTION:A Study to Evaluate the Efficacy and Safety Study of Povorcitin
 ib in Participants With Inadequately Controlled Moderate to Severe Asthma\
 n\nPrimary completion date: 2026-11-20 (estimated)\nOriginally planned: 20
 25-07-21 (+16.0 months)\nPhase 2 · Respiratory · Moderate to Severe Asth
 ma\nEnrollment: 247 · Sites: 82\n\nPrimary completion = last participant'
 s primary-endpoint data collected\; topline results usually follow weeks t
 o months later. Sponsor-reported\, often an estimate. Not investment advic
 e.\n\nhttps://datacutoff.com/radar.html?nct=NCT05851443\nhttps://c
 linicaltrials.gov/study/NCT05851443
URL:https://datacutoff.com/radar.html?nct=NCT05851443
CATEGORIES:Respiratory,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06212999-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20261226
DTEND;VALUE=DATE:20261227
SUMMARY:STOP-HS LTE readout (P3) · Incyte Corporation $INCY
DESCRIPTION:A Study to Evaluate the Long-Term Safety and Efficacy of Povorc
 itinib in Participants With Moderate to Severe Hidradenitis Suppurativa\n\
 nPrimary completion date: 2026-12-26 (estimated)\nPhase 3 · Infectious ·
  Hidradenitis Suppurativa (HS)\nEnrollment: 617 · Sites: 165\n\nPrimary c
 ompletion = last participant's primary-endpoint data collected\; topline r
 esults usually follow weeks to months later. Sponsor-reported\, often an e
 stimate. Not investment advice.\n\nhttps://datacutoff.com/radar.ht
 ml?nct=NCT06212999\nhttps://clinicaltrials.gov/study/NCT06212999
URL:https://datacutoff.com/radar.html?nct=NCT06212999
CATEGORIES:Infectious,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07023627-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270427
DTEND;VALUE=DATE:20270428
SUMMARY:MAESTRA 1 readout (P2) · Incyte Corporation $INCY
DESCRIPTION:A Study of INCB123667 in Participants With Platinum-Resistant O
 varian Cancer With Cyclin E1 Overexpression\n\nPrimary completion date: 20
 27-04-27 (estimated)\nPhase 2 · Oncology · Ovarian Cancer\nEnrollment: 1
 60 · Sites: 74\n\nPrimary completion = last participant's primary-endpoin
 t data collected\; topline results usually follow weeks to months later. S
 ponsor-reported\, often an estimate. Not investment advice.\n\nhttps://tri
 alsonar.netlify.app/radar.html?nct=NCT07023627\nhttps://clinicaltrials.gov
 /study/NCT07023627
URL:https://datacutoff.com/radar.html?nct=NCT07023627
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06804811-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Ruxolitinib Cream readout (P3) · Incyte Corporation $INCY
DESCRIPTION:A Study to Evaluate the Efficacy and Safety of Ruxolitinib Crea
 m in Children (6 to < 12 Years Old) With Nonsegmental Vitiligo\n\nPrimary 
 completion date: 2027-04-30 (estimated)\nPhase 3 · Immuno · NonSegmental
  Vitiligo\nEnrollment: 250 · Sites: 78\n\nPrimary completion = last parti
 cipant's primary-endpoint data collected\; topline results usually follow 
 weeks to months later. Sponsor-reported\, often an estimate. Not investmen
 t advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06804811\nht
 tps://clinicaltrials.gov/study/NCT06804811
URL:https://datacutoff.com/radar.html?nct=NCT06804811
CATEGORIES:Immuno,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05090891-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270730
DTEND;VALUE=DATE:20270731
SUMMARY:Progress readout (P2) · Incyte Corporation $INCY
DESCRIPTION:To Assess the Efficacy\, Safety\, and Tolerability of INCB00092
 8 in Participants With Fibrodysplasia Ossificans Progressiva\n\nPrimary co
 mpletion date: 2027-07-30 (estimated)\nOriginally planned: 2023-11-05 (+44
 .8 months)\nPhase 2 · Immuno · Fibrodysplasia Ossificans Progressiva (FO
 P)\nEnrollment: 98 · Sites: 24\n\nPrimary completion = last participant's
  primary-endpoint data collected\; topline results usually follow weeks to
  months later. Sponsor-reported\, often an estimate. Not investment advice
 .\n\nhttps://datacutoff.com/radar.html?nct=NCT05090891\nhttps://cl
 inicaltrials.gov/study/NCT05090891
URL:https://datacutoff.com/radar.html?nct=NCT05090891
CATEGORIES:Immuno,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06465433-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270829
DTEND;VALUE=DATE:20270830
SUMMARY:Tafasitamab readout (P2) · Incyte Corporation $INCY
DESCRIPTION:Extension Study to Provide Continued Treatment for Patients Wit
 h Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
 \n\nPrimary completion date: 2027-08-29 (estimated)\nPhase 2 · Oncology 
 · Hematologic Malignancies\nEnrollment: 25 · Sites: 5\n\nPrimary complet
 ion = last participant's primary-endpoint data collected\; topline results
  usually follow weeks to months later. Sponsor-reported\, often an estimat
 e. Not investment advice.\n\nhttps://datacutoff.com/radar.html?nct
 =NCT06465433\nhttps://clinicaltrials.gov/study/NCT06465433
URL:https://datacutoff.com/radar.html?nct=NCT06465433
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07104565-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270923
DTEND;VALUE=DATE:20270924
SUMMARY:INCA000585 readout (P2) · Incyte Corporation $INCY
DESCRIPTION:Study to Assess the Safety and Tolerability of Tafasitamab in A
 dult Participants With Primary Autoimmune Blood Cell Disorders\n\nPrimary 
 completion date: 2027-09-23 (estimated)\nPhase 2 · Cardio-Met · Immune T
 hrombocytopenia\nEnrollment: 56 · Sites: 39\n\nPrimary completion = last 
 participant's primary-endpoint data collected\; topline results usually fo
 llow weeks to months later. Sponsor-reported\, often an estimate. Not inve
 stment advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT0710456
 5\nhttps://clinicaltrials.gov/study/NCT07104565
URL:https://datacutoff.com/radar.html?nct=NCT07104565
CATEGORIES:Cardio-Met,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06585774-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270928
DTEND;VALUE=DATE:20270929
SUMMARY:AXemplify-357 readout (P3) · Incyte Corporation $INCY
DESCRIPTION:A Study to Evaluate Axatilimab and Corticosteroids as Initial T
 reatment for Chronic Graft-Versus-Host Disease\n\nPrimary completion date:
  2027-09-28 (estimated)\nPhase 3 · Respiratory · Chronic Graft-versus-ho
 st-disease\nEnrollment: 240 · Sites: 133\n\nPrimary completion = last par
 ticipant's primary-endpoint data collected\; topline results usually follo
 w weeks to months later. Sponsor-reported\, often an estimate. Not investm
 ent advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT06585774\n
 https://clinicaltrials.gov/study/NCT06585774
URL:https://datacutoff.com/radar.html?nct=NCT06585774
CATEGORIES:Respiratory,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT02955940-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Ruxolitinib readout (P2) · Incyte Corporation $INCY
DESCRIPTION:An Open-Label Study to Enable Continued Treatment Access for Su
 bjects Previously Enrolled in Studies of Ruxolitinib\n\nPrimary completion
  date: 2027-09-30 (estimated)\nOriginally planned: 2018-11 (+106.9 months)
 \nPhase 2 · Oncology · Pancreatic Cancer\, Colorectal Cancer (CRC)\, Bre
 ast Cancer\nEnrollment: 10 · Sites: 9\n\nPrimary completion = last partic
 ipant's primary-endpoint data collected\; topline results usually follow w
 eeks to months later. Sponsor-reported\, often an estimate. Not investment
  advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT02955940\nhtt
 ps://clinicaltrials.gov/study/NCT02955940
URL:https://datacutoff.com/radar.html?nct=NCT02955940
CATEGORIES:Oncology,Phase 2
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07214779-pcd@trialsonar.netlify.app
DTSTAMP:20261118T125025Z
DTSTART;VALUE=DATE:20271012
DTEND;VALUE=DATE:20271013
SUMMARY:MAESTRA 2 readout (P3) · Incyte Corporation $INCY
DESCRIPTION:Study to Evaluate INCB123667 Versus Investigator's Choice of Ch
 emotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyc
 lin E1 Overexpression\n\nPrimary completion date: 2027-10-12 (estimated)\n
 Originally planned: 2028-11-15 (-13.1 months)\nPhase 3 · Oncology · Ovar
 ian Cancer\nEnrollment: 13 · Sites: 198\n\nPrimary completion = last part
 icipant's primary-endpoint data collected\; topline results usually follow
  weeks to months later. Sponsor-reported\, often an estimate. Not investme
 nt advice.\n\nhttps://datacutoff.com/radar.html?nct=NCT07214779\nh
 ttps://clinicaltrials.gov/study/NCT07214779
URL:https://datacutoff.com/radar.html?nct=NCT07214779
CATEGORIES:Oncology,Phase 3
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
